<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The <z:chebi fb="11" ids="22586">antioxidant</z:chebi> compound <z:chebi fb="0" ids="30314">alpha-lipoic acid</z:chebi> (alpha-LA) possesses <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> and anti-<z:hpo ids='HP_0001513'>obesity</z:hpo> properties </plain></SENT>
<SENT sid="1" pm="."><plain>In the hypothalamus, alpha-LA suppresses appetite and prevents <z:hpo ids='HP_0001513'>obesity</z:hpo> by inhibiting <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) </plain></SENT>
<SENT sid="2" pm="."><plain>Given the therapeutic potential of alpha-LA for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo>, and the importance of AMPK in beta cells, we examined the effect of alpha-LA on pancreatic beta cell function </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: Isolated rat islets and MIN6 beta cells were treated acutely (15-90 min) or chronically (18-24 h) with alpha-LA or the known AMPK-activating compounds 5'-amino-<z:chebi fb="0" ids="14434,16069">imidazole</z:chebi>-4-<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi> <z:chebi fb="0" ids="18254">ribonucleoside</z:chebi> (AICAR) and <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Insulin secretion, the AMPK-signalling pathway, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function and cell growth were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0011009'>Acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment of islets and MIN6 cells with alpha-LA led to dose-dependent rises in phosphorylation of the AMPK alpha-subunit and <z:chebi fb="0" ids="15351">acetyl CoA</z:chebi> carboxylase </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> exposure to alpha-LA, AICAR or <z:chebi fb="0" ids="6801">metformin</z:chebi> caused a reduction in insulin secretion </plain></SENT>
<SENT sid="7" pm="."><plain>alpha-LA inhibited the p70 s6 kinase translational control pathway, and inhibited MIN6 growth in a manner similar to <z:chebi fb="0" ids="9168">rapamycin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Unlike AICAR and <z:chebi fb="0" ids="6801">metformin</z:chebi>, alpha-LA also acutely inhibited insulin secretion </plain></SENT>
<SENT sid="9" pm="."><plain>Examination of the effect of alpha-LA on <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function showed that <z:hpo ids='HP_0011009'>acute</z:hpo> treatment with this compound elevated reactive oxygen species (ROS) production and enhanced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> depolarisation induced by Ca(2+) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: This study is the first to demonstrate that alpha-LA directly affects beta cell function </plain></SENT>
<SENT sid="11" pm="."><plain>The <z:hpo ids='HP_0011010'>chronic</z:hpo> effects of alpha-LA include AMPK activation and reductions in insulin secretion and content, and cell growth </plain></SENT>
<SENT sid="12" pm="."><plain>Acutely, alpha-LA also inhibits insulin secretion, an effect probably involving the ROS-induced impairment of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function </plain></SENT>
</text></document>